NONMELANOMA SKIN CANCER IN A HEART TRANSPLANT PATIENT: A CASE REPORT AND REVIEW OF THE LITERATURE

Overview

Journal Acta Clin Croat

Specialty General Medicine

Date 2022 Nov 18

PMID 36398077

Authors

Lorena Karla Rudez

Tin Sklebar

Romana Ceovic

Affiliations

Soon will be listed here.

Abstract

Nonmelanoma skin cancers (NMSC) are the most common malignancies in solid organ transplant recipients. The most common types of skin cancer in these patients are squamous cell carcinoma (SCC), followed by basal cell carcinoma. In immunosuppressed patients, specifically patients after solid organ transplantation, these carcinomas tend to be more aggressive and have a much higher incidence of metastasizing compared to general population. We present a case of a patient who developed numerous SCCs after successful heart transplantation. SCCs which occurred in our patient were mostly treated surgically. However, the lesion on the scalp relapsed after it had been treated surgically three times and therefore superficial x-ray radiation therapy was administered due to its localization and extensive size. In the next year, five more new SCCs occurred throughout the patient's body and all of them were removed surgically. Soon afterwards, the patient died from adenocarcinoma of the colon which rapidly progressed and metastasized.

References

Asleh R, Clavell A, Pereira N, Smith B, Briasoulis A, Alnsasra H . Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. J Am Coll Cardiol. 2019; 73(21):2676-2688. DOI: 10.1016/j.jacc.2019.03.499. View

Brodland D, Zitelli J . Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992; 27(2 Pt 1):241-8. DOI: 10.1016/0190-9622(92)70178-i. View

Lindelof B, Sigurgeirsson B, Tegner E, Larko O, Johannesson A, Berne B . PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol. 1999; 141(1):108-12. DOI: 10.1046/j.1365-2133.1999.02928.x. View

Veness M . Aggressive skin cancers in a cardiac transplant recipient. Australas Radiol. 1997; 41(4):363-6. DOI: 10.1111/j.1440-1673.1997.tb00734.x. View

Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B . Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003; 89(7):1221-7. PMC: 2394311. DOI: 10.1038/sj.bjc.6601219. View

Metchnikoff C, Mully T, Singer J, Golden J, Arron S . The 7th edition AJCC staging system for cutaneous squamous cell carcinoma accurately predicts risk of recurrence for heart and lung transplant recipients. J Am Acad Dermatol. 2012; 67(5):829-35. PMC: 3345300. DOI: 10.1016/j.jaad.2012.01.010. View

Ulrich C, Schmook T, Sachse M, Sterry W, Stockfleth E . Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg. 2004; 30(4 Pt 2):622-7. DOI: 10.1111/j.1524-4725.2004.30147.x. View

Harwood C, Mesher D, McGregor J, Mitchell L, Leedham-Green M, Raftery M . A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. Am J Transplant. 2012; 13(1):119-29. DOI: 10.1111/j.1600-6143.2012.04292.x. View

Hunt S . Malignancy in organ transplantation: heart. Transplant Proc. 2002; 34(5):1874-6. DOI: 10.1016/s0041-1345(02)03105-6. View

10.

Wang Y, Chi N, Chou N, Huang S, Wang C, Wu I . Malignancy After Heart Transplantation Under Everolimus Versus Mycophenolate Mofetil Immunosuppression. Transplant Proc. 2016; 48(3):969-73. DOI: 10.1016/j.transproceed.2015.12.071. View

11.

Fortina A, Caforio A, Piaserico S, Alaibac M, Tona F, Feltrin G . Skin cancer in heart transplant recipients: frequency and risk factor analysis. J Heart Lung Transplant. 2000; 19(3):249-55. DOI: 10.1016/s1053-2498(99)00137-0. View

12.

Salgo R, Gossmann J, Schofer H, Kachel H, Kuck J, Geiger H . Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010; 10(6):1385-93. DOI: 10.1111/j.1600-6143.2009.02997.x. View

13.

Doesch A, Muller S, Konstandin M, Celik S, Kristen A, Frankenstein L . Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal. Transplant Proc. 2010; 42(9):3694-9. DOI: 10.1016/j.transproceed.2010.07.107. View

14.

Yagdi T, Sharples L, Tsui S, Large S, Parameshwar J . Malignancy after heart transplantation: analysis of 24-year experience at a single center. J Card Surg. 2009; 24(5):572-9. DOI: 10.1111/j.1540-8191.2009.00858.x. View

15.

de Gruijl F . Photocarcinogenesis: UVA vs. UVB radiation. Skin Pharmacol Appl Skin Physiol. 2002; 15(5):316-20. DOI: 10.1159/000064535. View

16.

Ulrich C, Arnold R, Frei U, Hetzer R, Neuhaus P, Stockfleth E . Skin changes following organ transplantation: an interdisciplinary challenge. Dtsch Arztebl Int. 2014; 111(11):188-94. PMC: 3977442. DOI: 10.3238/arztebl.2014.0188. View

17.

Ulrich C, Kanitakis J, Stockfleth E, Euvrard S . Skin cancer in organ transplant recipients--where do we stand today?. Am J Transplant. 2008; 8(11):2192-8. DOI: 10.1111/j.1600-6143.2008.02386.x. View

18.

Van Keer J, Droogne W, Van Cleemput J, Voros G, Rega F, Meyns B . Cancer After Heart Transplantation: A 25-year Single-center Perspective. Transplant Proc. 2016; 48(6):2172-7. DOI: 10.1016/j.transproceed.2016.03.037. View

19.

Otley C, Pittelkow M . Skin cancer in liver transplant recipients. Liver Transpl. 2000; 6(3):253-62. DOI: 10.1053/lv.2000.6352. View

20.

Primc D, Racki S, Arnol M, Marinovic M, Fucak-Primc A, Muzur A . THE BEGINNINGS OF KIDNEY TRANSPLANTATION IN SOUTH-EAST EUROPE. Acta Clin Croat. 2020; 59(1):135-140. PMC: 7382875. DOI: 10.20471/acc.2020.59.01.16. View